Your about to leave the site and are being redirected to another site. Would you like to leave this site?

Click for Additional Indications

1 of 2

INDICATIONS

Metastatic Merkel cell carcinoma (mMCC)

BAVENCIO® (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Click for Additional Indications

2 of 2

INDICATIONS

Locally advanced or metastatic urothelial carcinoma (UC)

BAVENCIO® (avelumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

  • Have disease progression during or following platinum-containing chemotherapy
  • Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

For

METASTATIC MERKEL CELL CARCINOMA (mMCC)

For previously treated 

LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (UC)